Assyro AI

Orange Book product · Generic (ANDA)

SUMATRIPTAN AND NAPROXEN SODIUM

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Generic (ANDA)ANDA 202803TE ABRX SUN PHARM

At a glance

Jul 20, 2018

Approved

Generic (ANDA)

Application

AB

TE code

None

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jul 20, 2018

    8 yr ago

  2. Today

Pharmaceutical detail

Active ingredient

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Strength

500MG;EQ 85MG BASE

Dosage form

TABLET

Route

ORAL

TE code

AB

Application

ANDA 202803

Product number

001

Marketing status

RX

Reference listed drug (RLD)

No

Reference standard (RS)

No

Active-ingredient family

View full family

Generic (ANDA) of NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.